Leptomeningeal Carcinomatosis in a Patient with Pancreatic Cancer Responding to Nab-Paclitaxel plus Gemcitabine

被引:6
|
作者
Ceccon, Garry [1 ,2 ]
Wollring, Michael [1 ,2 ]
Brunn, Anna [2 ,3 ]
Deckert, Martina [2 ,3 ]
Waldschmidt, Dirk [2 ,4 ,6 ,7 ,8 ,9 ]
Fink, Gereon R. [1 ,2 ,5 ]
Galldiks, Norbert [1 ,2 ,5 ,6 ,7 ,8 ,9 ]
机构
[1] Univ Cologne, Fac Med, Dept Neurol, Cologne, Germany
[2] Univ Cologne, Univ Hosp Cologne, Cologne, Germany
[3] Univ Cologne, Fac Med, Dept Neuropathol, Cologne, Germany
[4] Univ Cologne, Fac Med, Dept Hepato & Gastroenterol, Cologne, Germany
[5] Forschungszentrum Julich, Inst Neurosci & Med INM 3, Leo Brandt Str 5, DE-52425 Julich, Germany
[6] Univ Aachen, Ctr Integrated Oncol CIO, Aachen, Germany
[7] Univ Bonn, Bonn, Germany
[8] Univ Cologne, Cologne, Germany
[9] Univ Duesseldorf, Dusseldorf, Germany
来源
CASE REPORTS IN ONCOLOGY | 2020年 / 13卷 / 01期
关键词
Blood-brain barrier; Leptomeningeal metastasis; Carcinomatous meningitis; FOLFIRINOX; ALBUMIN-BOUND PACLITAXEL; BREAST-CANCER; PHASE-II; NEOPLASTIC MENINGITIS; NEOADJUVANT TRIAL; BRAIN; CHEMOTHERAPY; TRASTUZUMAB; COMBINATION; TUMOR;
D O I
10.1159/000504697
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Leptomeningeal carcinomatosis is an extremely rare, but devastating complication in pancreatic cancer patients with a poor prognosis despite multimodal treatment. We present a 51-year-old male patient with the very rare condition of leptomeningeal carcinomatosis originating from pancreatic cancer. He presented to our hospital with severe headache and neck stiffness 30 months after systemic chemotherapy. Cerebral and spinal MRI as well as cerebrospinal fluid examination confirmed the diagnosis of leptomeningeal carcinomatosis. The patient responded to gemcitabine plus nab-paclitaxel in terms of elimination of tumor cells from the CSF and concurrent clinical improvement for 3 months. The observed findings suggest that the combination of gemcitabine plus nab-paclitaxel is potentially effective in affected cerebrospinal fluid of pancreatic carcinoma patients.
引用
收藏
页码:35 / 42
页数:8
相关论文
共 50 条
  • [11] Predictors of vulnerability to nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer
    Iede, Kiyotsugu
    Yamada, Terumasa
    Tominaga, Shusei
    ANNALS OF ONCOLOGY, 2023, 34 : S1453 - S1453
  • [12] Gemcitabine plus Nab-Paclitaxel with chemoradiation in locally advanced pancreatic cancer (LAPC)
    Olowokure, Olugbenga
    Torregroza-Sanchez, Maria Patricia
    Bedoya-Apraez, Ivan Dario
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2013, 4 (02) : E16 - E18
  • [13] Gemcitabine plus nab-paclitaxel for locally advanced or borderline resectable pancreatic cancer
    Tsujimoto, Akiko
    Sudo, Kentaro
    Nakamura, Kazuyoshi
    Kita, Emiri
    Hara, Ryusuke
    Takayama, Wataru
    Ishii, Hiroshi
    Yamaguchi, Taketo
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [15] Nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreatic cancer: our experience
    Mare, M.
    Munao, S.
    Germana, S.
    Colarossi, C.
    Sciacca, D.
    Giuffrida, D.
    Giannone, G.
    ANNALS OF ONCOLOGY, 2017, 28
  • [16] Gemcitabine plus nab-paclitaxel for locally advanced or borderline resectable pancreatic cancer
    Akiko Tsujimoto
    Kentaro Sudo
    Kazuyoshi Nakamura
    Emiri Kita
    Ryusuke Hara
    Wataru Takayama
    Hiroshi Ishii
    Taketo Yamaguchi
    Scientific Reports, 9
  • [17] A Retrospective Study of Gemcitabine Plus Nab-Paclitaxel for Advanced Pancreatic Cancer Refractory to Gemcitabine Monotherapy
    Nishioka, Mariko
    Okano, Naohiro
    Wakabayashi, Masashi
    Ikeno, Takashi
    Hayashi, Masato
    Mizutani, Tomonori
    Nagashima, Fumio
    Furuse, Junji
    ANTICANCER RESEARCH, 2024, 44 (03) : 1233 - 1239
  • [18] Gemcitabine plus nab-paclitaxel in Japan
    Ioka, Tatsuya
    Katayama, Kazuhiro
    Ookawa, Kazuyoshi
    Takahashi, Hidenori
    Teshima, Teruki
    ANNALS OF ONCOLOGY, 2016, 27
  • [19] Clinical and translational results of a phase I study, tocilizumab plus gemcitabine/nab-paclitaxel in patient with gemcitabine/nab-paclitaxel-refractory metastatic pancreatic cancer
    Mitsunaga, Shuichi
    Ikeda, Masafumi
    Aoki, Kazunori
    Yamaguchi, Kyoko
    Sawada, Noriaki
    Fujii, Etsuko
    Nishidate, Masanobu
    Fujitomo, Takashi
    Mizuno, Hideaki
    Kayukawa, Yoko
    Kato, Atsuhiko
    Makikawa, Mayu
    Imaoka, Hiroshi
    Sasaki, Mitsuhito
    Watanabe, Kazuo
    Tsunoda, Hiroyuki
    Terao, Kimio
    Ochiai, Atsushi
    CANCER RESEARCH, 2022, 82 (12)
  • [20] Cost-effectiveness of nab-paclitaxel plus gemcitabine versus erlotinib plus gemcitabine in metastatic pancreatic cancer
    Chiorean, E. Gabriela
    Whiting, Scott
    Binder, Gary
    Dranitsaris, George
    Manax, Victoria
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)